To date, tau-PET tracers have been used to localize and quantify tau in cognitively normal older controls, individuals with mild cognitive impairment (MCI) and individuals with AD or other neurodegenerative diseases where abnormal tau accumulation is a feature of the pathophysiology (Groot et al., 2022). This evidence concerns the gene MAPT and Cognitive impairment.